Related references
Note: Only part of the references are listed.2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Outcomes of Nonagenarians with Acute Myocardial Infarction with or without Coronary Intervention
Seok Oh et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study
Ting-Yung Chang et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Association between baseline smoking status and clinical outcomes following myocardial infarction
Seok Oh et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
S. D. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
Jong Ha Baek et al.
DIABETES & METABOLISM JOURNAL (2022)
The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors
Warren Huang et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2021)
Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
Dimitrios Ioannis Patoulias et al.
WORLD JOURNAL OF CARDIOLOGY (2021)
Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities
Rozalina G. McCoy et al.
DIABETES CARE (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000-2019
Kyung Ae Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2021)
Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study
Camilla Bang et al.
DIABETES OBESITY & METABOLISM (2020)
Minireview: are SGLT2 inhibitors heart savers in diabetes?
Petra Grubic Rotkvic et al.
HEART FAILURE REVIEWS (2020)
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
Marc P. Bonaca et al.
CIRCULATION (2020)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka et al.
Lancet Diabetes & Endocrinology (2020)
Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
Hsin-Fu Lee et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
2018 ESC/EACTS Guidelines on myocardial revascularization
Franz-Josef Neumann et al.
EUROPEAN HEART JOURNAL (2019)
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Chenguang Li et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome
Angelo Avogaro et al.
DIABETES & VASCULAR DISEASE RESEARCH (2019)
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Hiddo J. L. Heerspink et al.
DIABETOLOGIA (2019)
Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
FRONTIERS IN ENDOCRINOLOGY (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
Francesca Iannantuoni et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status
Bo-Yeon Kim et al.
DIABETES & METABOLISM JOURNAL (2019)
Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis
B. M. Mishriky et al.
DIABETES & METABOLISM (2018)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Mitochondrial dysfunction in pathophysiology of heart failure
Bo Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
Laween Uthman et al.
FRONTIERS IN PHYSIOLOGY (2018)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Frederik Persson et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
Mei-Tzu Wang et al.
CARDIOVASCULAR DIABETOLOGY (2017)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi et al.
EUROPEAN HEART JOURNAL (2016)
Chronic Heart Failure and Inflammation What Do We Really Know?
Sarah A. Dick et al.
CIRCULATION RESEARCH (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism
Bo Ahren et al.
DIABETOLOGIA (2016)
Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats
Hiromichi Murase et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
The safety of dipeptidyl peptidase-4 ( DPP-4) inhibitors or sodium- glucose cotransporter 2 ( SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta- analysis
Pawel Kawalec et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Regulation of the cardiac Na+/H+ exchanger in health and disease
Shigeo Wakabayashi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
SGLT2 versus DPP4 inhibitors for type 2 diabetes
Andre J. Scheen
LANCET DIABETES & ENDOCRINOLOGY (2013)
Third Universal Definition of Myocardial Infarction
Kristian Thygesen et al.
CIRCULATION (2012)
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
L. J. M. Boonman-de Winter et al.
DIABETOLOGIA (2012)
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
AG Bertoni et al.
DIABETES CARE (2004)
Share Paper
